Stay informed about the latest updates and insights from Conscio Group as well as key developments in the pharmaceutical industry, all driven by our commitment to improving health through science.

  • 15 May 2025

    From Analytical Similarity to Clinical Data: Tailoring Evidence for Biosimilar Approval

    Registration is now open for our free expert-led webinar on the evolving evidence requirements for biosimilar approval.

  • 6 May 2025

    The Benefits of FTE Contracts for Pharmaceutical Companies

    How can an FTE-based partnership with a CRO transform your pharmaceutical development?

  • 8 April 2025

    Batch Release Testing and QP Certification: The Backbone of Pharmaceutical Quality Assurance

    Are strict pharmaceutical regulations slowing your EU market entry? You're not alone. Navigating the complex landscape of batch release testing can be challenging, particularly for pharmaceutical manufacturers outside the EU.

  • 7 April 2025

    Conscio Group Appoints Gary Chambers as Executive Vice President of Strategy and Marketing

    April 3, 2025 – Conscio Group, a leading scientific service provider for the pharmaceutical industry, announces the appointment of Gary Chambers as Executive Vice President (EVP) of Strategy and Marketing.

  • 25 November 2024

    Expediting Biosimilar development: Streamlining the path from research to market

    A free webinar on the future of biosimilar pathway to approval is now available for registration.

  • 2 October 2024

    Conscio Group and Kiel Labs Announce Strategic Partnership

    Conscio Group, a European network of GMP/GLP/GCP/IEC-certified contract R&D service providers, and Kiel Laboratories, Inc., a leading U.S. pharmaceutical research and development company, today announced a strategic partnership to enhance drug development capabilities and market access for their respective clients.

  • 26 September 2024

    Business Development Manager Environment – Slovakia

    EL Labs

    Environmental analysis services, batch release testing, and much more.

  • 4 September 2024

    Meet us at the heart of Pharma at CPHI 2024

    Conscio Group is attending CPHI 2024 in Milan, Italy.

  • 10 June 2024

    Vorteile sequentieller Designs in Bioäquivalenzstudien

    Entdecken Sie die Leistungsfähigkeit sequentieller Designs für Bioäquivalenzstudien, einem entscheidenden Schritt in der Entwicklung von Generika: Ihre praktische Umsetzung, statistische Analyse und das Wohlbefinden der Freiwilligen.

  • 14 May 2024

    A new partnership with Reference Analytics GmbH

    The Conscio Group is expanding its range of services in Austria by acquiring Reference Analytics GmbH.